Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of DA-5223 Formulations in Healthy Adults
NCT07633691Phase 1Completed
- Sponsor
- Dong-A ST
- Start
- Jun 2026
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DA-5223 (4 arms), sponsored by Dong-A ST. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration and Maximum Observed Plasma Concentration. Started Jun 2026; status: completed.
02
Drugs
DA-5223
Beyond the preview
Go deeper on NCT07633691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07633691.